ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,299.60
      0.01%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.015
      0.18%
      Bitcoin
      63,513.23
      -0.17%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Mirum Pharmaceuticals Inc (MIRM) Quote

      Mirum Pharmaceuticals Inc

      Mirum Pharmaceuticals Inc (MIRM)

      NASDAQ
      38.96
      -0.39
      (-0.99%)
      Closed September 20 4:00PM
      Delayed by 15 minutes
      38.96
      0.00
      ( 0.00% )
      Pre Market: 4:05AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      38.96
      Bid
      19.12
      Ask
      62.33
      Volume
      -
      0.00 Day's Range 0.00
      23.14 52 Week Range 45.23
      Market Cap
      1.859B
      Previous Close
      38.96
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      557,244
      Shares Outstanding
      47,707,204
      Dividend Yield
      -
      PE Ratio
      -11.37
      Earnings Per Share (EPS)
      -3.43
      Revenue
      186.37M
      Net Profit
      -163.42M

      About Mirum Pharmaceuticals Inc

      Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $38.96. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.14 to $ 45.23.

      Mirum Pharmaceuticals currently has 47,707,204 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.86 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.37.

      Ask ADVFN Intelligence (AI)

      Mirum Pharmaceuticals (MIRM) Options Flow Summary

      MIRM Options Flow

      Overall Flow

      Bearish

      Net Premium

      -40k

      Calls / Puts

      0.00%

      Buys / Sells

      0.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      MIRM Latest News

      More News

      Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...

      September 10 2024
      Business Wire

      Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

      August 28 2024
      Business Wire

      Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

      August 09 2024
      Business Wire

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 07 2024
      Edgar (US Regulatory)

      Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

      Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC...

      August 07 2024
      Business Wire

      Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

      Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the...

      July 31 2024
      Business Wire

      Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

      Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the...

      July 25 2024
      Business Wire

      Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

      July 10 2024
      Business Wire

      Approbation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFIC

      La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de trois mois et plus. L’approbation fait suite à l’avis...

      July 08 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-2.52-6.0752169720341.4841.4836.859168294238.79905812CS
      4-2.34-5.6658595641641.345.2336.859142930240.79076069CS
      124.5313.157130409534.4345.2333.4555724440.00107744CS
      2612.8349.100650593226.1345.2323.1458706933.07235448CS
      528.2126.699186991930.7545.2323.1458500431.13002631CS
      15619.1596.668349318519.8145.2312.8242965626.98670953CS
      26029.65318.4747583249.3145.236.512630858725.53708842CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NUKKNukkleus Inc
      $ 0.3715
      (74.82%)
      		3.33M
      TGLTreasure Global Inc
      $ 0.9294
      (36.62%)
      		460.26k
      ULYUrgent ly Inc
      $ 1.12
      (26.97%)
      		333.41k
      GSIWGarden Stage Ltd
      $ 1.625
      (21.27%)
      		824.92k
      BDRXBiodexa Pharmaceuticals PLC
      $ 0.35
      (19.82%)
      		3.51k
      PRFXPainReform Ltd
      $ 0.60
      (-22.19%)
      		1.95k
      ZJYLJin Medical International Ltd
      $ 3.24
      (-20.59%)
      		1.7k
      FRESFresh2 Group Ltd
      $ 1.39
      (-19.65%)
      		88
      ADTXAditxt Inc
      $ 0.3111
      (-18.69%)
      		26.55k
      MYNZMainz BioMed NV
      $ 0.2006
      (-17.45%)
      		144.2k
      NUKKNukkleus Inc
      $ 0.3715
      (74.82%)
      		3.33M
      GSIWGarden Stage Ltd
      $ 1.625
      (21.27%)
      		824.92k
      TGLTreasure Global Inc
      $ 0.9294
      (36.62%)
      		460.26k
      ULYUrgent ly Inc
      $ 1.12
      (26.97%)
      		333.41k
      INTCIntel Corporation
      $ 22.70
      (3.94%)
      		322.42k

      MIRM Discussion

      View Posts
      Monksdream Monksdream 1 week ago
      MIRM range bound
      👍️0
      Ganz Ganz 2 years ago
      I agree !
      👍️0
      historyperson historyperson 2 years ago
      I'm not sure there's a more intriguing small pharma out there. Too bad I only have 50 shares. If AUPH gets bought out before this one, that'll change.
      >90% institutionally owned with only 36m shares outstanding.
      Huge potential. Could easily see $50/share with the way LIVMARLI® is selling...
      👍️0
      Ganz Ganz 2 years ago
      Float, smote, keep an eye on this one.
      👍️0
      Cosa Cosa 2 years ago
      The float is so small
      👍️0
      Ganz Ganz 3 years ago
      Not many peeps here, this is a breakout stock , unusual / positive activity lately
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MIRM Video Chart 12-18-2019 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      CyrusDaVirus CyrusDaVirus 5 years ago
      Nice
      👍️0
      zc182 zc182 5 years ago
      Just took a position today. Looking good all the way around. Really impressed with their website.
      👍️0

      Your Recent History

      NASDAQ
      MIRM
      Mirum Pharmaceuticals
      Delayed Upgrade Clock